Key result
Propranolol and pilsicainide were the most cost-effective rate- and rhythm-control drugs for treating atrial fibrillation in Korea, with incremental cost-effectiveness ratios of -$577/QALY and $332/QALY compared to atenolol.
Why the study?
Although the economic and mortality burden of AF is substantial, it remains unclear which treatment strategies for rate and rhythm control are most cost-effective.
Which rate- and rhythm-control drugs are most cost-effective for treating atrial fibrillation in Korean patients?
Observational (n=268,149)
Which rate- and rhythm-control drugs are most cost-effective for treating atrial fibrillation in Korean patients?
Propranolol and pilsicainide appear to be the most cost-effective rate- and rhythm-control drugs, respectively, for patients with atrial fibrillation in Korea.
Answers are grounded in this paper and cite their sources.
May inform cost-effective AF choices in Korea; leaves open need for randomized confirmation.
PURPOSE: Although the economic and mortality burden of atrial fibrillation (AF) is substantial, it remains unclear which treatment strategies for rate and rhythm control are most cost-effective. Consequently, economic factors can play an adjunctive role in guiding treatment selection. MATERIALS AND METHODS: We built a Markov chain Monte Carlo model using the Korean Health Insurance Review & Assessment Service database. Drugs for rate control and rhythm control in AF were analyzed. Cost-effective therapies were selected using a cost-effectiveness ratio, calculated by net cost and quality-adjusted life years (QALY). RESULTS: In the National Health Insurance Service data, 268149 patients with prevalent AF (age ≥18 years) were identified between January 1, 2013 and December 31, 2015. Among them, 212459 and 55690 patients were taking drugs for rate and rhythm control, respectively. Atenolol cost $714/QALY. Among the rate-control medications, the cost of propranolol was lowest at $487/QALY, while that of carvedilol was highest at $1363/QALY. Among the rhythm-control medications, the cost of pilsicainide was lowest at $638/QALY, while that of amiodarone was highest at $986/QALY. Flecainide and propafenone cost $834 and $830/QALY, respectively. The cost-effectiveness threshold of all drugs was lower than $30000/QALY. Compared with atenolol, the rate-control drugs propranolol, betaxolol, bevantolol, bisoprolol, diltiazem, and verapamil, as well as the rhythm-control drugs sotalol, pilsicainide, flecainide, propafenone, and dronedarone, showed better incremental cost-effectiveness ratios. CONCLUSION: Propranolol and pilsicainide appear to be cost-effective in patients with AF in Korea assuming that drug usage or compliance is the same.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) conducted an observational in Atrial fibrillation (n=268,149). Rate- and rhythm-control drugs (Propranolol and Pilsicainide) vs. Atenolol was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER -$577/QALY for propranolol). Propranolol and pilsicainide were the most cost-effective rate- and rhythm-control drugs for treating atrial fibrillation in Korea, with incremental cost-effectiveness ratios of -$577/QALY and $332/QALY compared to atenolol.
Synapse has enriched 10 related papers. Consider them for comparative context: